PT3227339T - Recetores de antigénio quiméricos que têm como alvo o recetor 4 acoplado a proteína g e utilizações dos mesmos - Google Patents

Recetores de antigénio quiméricos que têm como alvo o recetor 4 acoplado a proteína g e utilizações dos mesmos

Info

Publication number
PT3227339T
PT3227339T PT158656330T PT15865633T PT3227339T PT 3227339 T PT3227339 T PT 3227339T PT 158656330 T PT158656330 T PT 158656330T PT 15865633 T PT15865633 T PT 15865633T PT 3227339 T PT3227339 T PT 3227339T
Authority
PT
Portugal
Prior art keywords
couple
protein
chimeric antigen
antigen receptors
targeting receptor
Prior art date
Application number
PT158656330T
Other languages
English (en)
Portuguese (pt)
Original Assignee
Eureka Therapeutics Inc
Memorial Sloan Kettering Cancer Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eureka Therapeutics Inc, Memorial Sloan Kettering Cancer Center filed Critical Eureka Therapeutics Inc
Publication of PT3227339T publication Critical patent/PT3227339T/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/15—Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cells; Myeloid precursor cells; Antigen-presenting cells, e.g. dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001129—Molecules with a "CD" designation not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/421—Immunoglobulin superfamily
    • A61K40/4211—CD19 or B4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4256—Tumor associated carbohydrates
    • A61K40/4257—Mucins, e.g. MUC-1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70517—CD8
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/7056—Lectin superfamily, e.g. CD23, CD72
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3061—Blood cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5156—Animal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/10041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/10043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/13043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Wood Science & Technology (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
PT158656330T 2014-12-05 2015-12-04 Recetores de antigénio quiméricos que têm como alvo o recetor 4 acoplado a proteína g e utilizações dos mesmos PT3227339T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201462088286P 2014-12-05 2014-12-05

Publications (1)

Publication Number Publication Date
PT3227339T true PT3227339T (pt) 2022-01-14

Family

ID=56092565

Family Applications (1)

Application Number Title Priority Date Filing Date
PT158656330T PT3227339T (pt) 2014-12-05 2015-12-04 Recetores de antigénio quiméricos que têm como alvo o recetor 4 acoplado a proteína g e utilizações dos mesmos

Country Status (26)

Country Link
US (5) US10633426B2 (enExample)
EP (2) EP4015534A1 (enExample)
JP (3) JP6919091B2 (enExample)
KR (1) KR102612367B1 (enExample)
CN (4) CN113683711A (enExample)
AU (2) AU2015357518B2 (enExample)
CA (1) CA2969864A1 (enExample)
CY (1) CY1125008T1 (enExample)
DK (1) DK3227339T3 (enExample)
ES (1) ES2899779T3 (enExample)
HR (1) HRP20211978T1 (enExample)
HU (1) HUE057777T2 (enExample)
IL (2) IL310130A (enExample)
LT (1) LT3227339T (enExample)
MX (2) MX385156B (enExample)
MY (1) MY192065A (enExample)
PH (1) PH12017501044A1 (enExample)
PL (1) PL3227339T3 (enExample)
PT (1) PT3227339T (enExample)
RS (1) RS62870B1 (enExample)
RU (1) RU2762359C2 (enExample)
SA (1) SA517381665B1 (enExample)
SG (2) SG11201704547RA (enExample)
SI (1) SI3227339T1 (enExample)
SM (1) SMT202200040T1 (enExample)
WO (1) WO2016090312A1 (enExample)

Families Citing this family (91)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI3227339T1 (sl) 2014-12-05 2022-02-28 Memorial Sloan-Kettering Cancer Center Himerni antigenski receptorji, ki ciljajo na receptor, povezan z G-proteinom, in njihova uporaba
EP3227324A4 (en) * 2014-12-05 2018-08-29 Memorial Sloan Kettering Cancer Center Antibodies targeting g-protein coupled receptor and methods of use
PT3298033T (pt) 2015-05-18 2020-09-22 Tcr2 Therapeutics Inc Composições e utilizações médicas para reprogramação de tcr utilizando proteínas de fusão
AU2017306432A1 (en) 2016-08-02 2019-03-21 TCR2 Therapeutics Inc. Compositions and methods for TCR reprogramming using fusion proteins
EP3495391A4 (en) 2016-08-05 2020-08-19 Y-Biologics Inc. ANTIBODIES AGAINST PROGRAMMED DEATH LIGAND 1 (PD-L1) AND USE OF IT
CA3036745A1 (en) 2016-10-07 2018-04-12 TCR2 Therapeutics Inc. Compositions and methods for t-cell receptors reprogramming using fusion proteins
CA3044593A1 (en) 2016-11-22 2018-05-31 TCR2 Therapeutics Inc. Compositions and methods for tcr reprogramming using fusion proteins
KR20250072712A (ko) 2016-12-02 2025-05-26 앤젤레스 테라퓨틱스, 인코포레이티드 합성 면역 수용체 및 이의 사용 방법
LT3565579T (lt) 2017-01-05 2023-09-11 Kahr Medical Ltd. Pd1-41bbl sulietas baltymas ir jo panaudojimo būdai
US11299530B2 (en) 2017-01-05 2022-04-12 Kahr Medical Ltd. SIRP alpha-CD70 fusion protein and methods of use thereof
US11566060B2 (en) 2017-01-05 2023-01-31 Kahr Medical Ltd. PD1-CD70 fusion protein and methods of use thereof
RU2769769C2 (ru) 2017-01-05 2022-04-05 Кахр Медикал Лтд. СЛИТЫЙ БЕЛОК SIRPα-4-1BBL И СПОСОБЫ ЕГО ПРИМЕНЕНИЯ
EP3581651A4 (en) * 2017-02-07 2021-05-12 Daiichi Sankyo Company, Limited ANTI-GPRC5D ANTIBODY AND MOLECULE WITH IT
WO2018200583A1 (en) 2017-04-26 2018-11-01 Eureka Therapeutics, Inc. Cells expressing chimeric activating receptors and chimeric stimulating receptors and uses thereof
AU2018313950A1 (en) 2017-08-09 2020-02-13 Juno Therapeutics, Inc. Methods for producing genetically engineered cell compositions and related compositions
MA49981A (fr) 2017-08-09 2020-06-17 Juno Therapeutics Inc Procédés et compositions de préparation de cellules génétiquement modifiées
US20200292526A1 (en) 2017-09-07 2020-09-17 Juno Therapeutics, Inc. Methods of identifying cellular attributes related to outcomes associated with cell therapy
EP4512823A3 (en) 2017-11-01 2025-05-14 Juno Therapeutics, Inc. Process for generating therapeutic compositions of engineered cells
US12031975B2 (en) 2017-11-01 2024-07-09 Juno Therapeutics, Inc. Methods of assessing or monitoring a response to a cell therapy
SG11202003657VA (en) 2017-11-01 2020-05-28 Juno Therapeutics Inc Process for producing a t cell composition
KR20200074997A (ko) 2017-11-01 2020-06-25 주노 쎄러퓨티크스 인코퍼레이티드 B-세포 성숙 항원에 특이적인 항체 및 키메릭 항원 수용체
US11564946B2 (en) 2017-11-01 2023-01-31 Juno Therapeutics, Inc. Methods associated with tumor burden for assessing response to a cell therapy
DK3703750T3 (da) 2017-11-01 2025-02-10 Juno Therapeutics Inc Kimæriske antigenreceptorer, der er specifikke for b-cellemodningsantigen, og som koder for polynukleotider
CN111655270A (zh) 2017-11-14 2020-09-11 纪念斯隆-凯特琳癌症中心 分泌il-36的免疫应答细胞及其用途
MA51210A (fr) 2017-12-01 2020-10-07 Juno Therapeutics Inc Procédés de dosage et de modulation de cellules génétiquement modifiées
MX2020005906A (es) 2017-12-08 2020-10-22 Juno Therapeutics Inc Marcadores fenotipicos para terapia celular y metodos relacionados.
MX2020005908A (es) 2017-12-08 2020-10-07 Juno Therapeutics Inc Proceso para producir una composicion de celulas t modificadas.
SG11202005228YA (en) 2017-12-08 2020-07-29 Juno Therapeutics Inc Serum-free media formulation for culturing cells and methods of use thereof
EP3774919A4 (en) * 2018-03-30 2021-12-29 Eureka Therapeutics, Inc. Constructs targeting cd22 and uses thereof
US12012461B2 (en) * 2018-05-16 2024-06-18 Janssen Biotech, Inc. Methods of treating cancers and enhancing efficacy of T cell redirecting therapeutics
KR20210044221A (ko) 2018-07-11 2021-04-22 카 메디컬 리미티드 Pd1-4-1bbl 변이체 융합 단백질 및 이의 사용 방법
US12134638B2 (en) 2018-07-11 2024-11-05 Kahr Medical Ltd. SIRPalpha-4-1BBL variant fusion protein and methods of use thereof
BR112021002245A2 (pt) 2018-08-09 2021-05-04 Juno Therapeutics Inc métodos para avaliar ácidos nucleicos integrados
MX2021001523A (es) 2018-08-09 2021-05-27 Juno Therapeutics Inc Procesos para generar células modificadas y composiciones de las mismas.
JP7672340B2 (ja) * 2018-10-19 2025-05-07 メモリアル スローン ケタリング キャンサー センター シアリルルイスａを標的とするキメラ抗原受容体およびその使用
US20220002669A1 (en) 2018-10-31 2022-01-06 Juno Therapeutics Gmbh Methods for selection and stimulation of cells and apparatus for same
JP7742773B2 (ja) * 2018-11-01 2025-09-22 ジュノー セラピューティクス インコーポレイテッド Ｇタンパク質共役受容体クラスｃグループ５メンバーｄ（ｇｐｒｃ５ｄ）に特異的なキメラ抗原受容体
EP3873943A2 (en) 2018-11-01 2021-09-08 Juno Therapeutics, Inc. Methods for treatment using chimeric antigen receptors specific for b-cell maturation antigen
ES2981569T3 (es) 2018-11-30 2024-10-09 Juno Therapeutics Inc Métodos de tratamiento usando terapia celular adoptiva
US12077592B2 (en) * 2019-01-18 2024-09-03 Janssen Biotech, Inc. GPRC5D chimeric antigen receptors and cells expressing the same
WO2020223535A1 (en) 2019-05-01 2020-11-05 Juno Therapeutics, Inc. Cells expressing a recombinant receptor from a modified tgfbr2 locus, related polynucleotides and methods
BR112021021200A2 (pt) 2019-05-01 2021-12-21 Juno Therapeutics Inc Células expressando um receptor quimérico de um locus cd247 modificado, polinucleotídeos relacionados e métodos
JP2022537700A (ja) 2019-06-12 2022-08-29 ジュノー セラピューティクス インコーポレイテッド 細胞媒介細胞傷害性療法と生存促進性ｂｃｌ２ファミリータンパク質の阻害剤との併用療法
EP4017527A1 (en) 2019-08-22 2022-06-29 Juno Therapeutics, Inc. Combination therapy of a t cell therapy and an enhancer of zeste homolog 2 (ezh2) inhibitor and related methods
CN114929360A (zh) 2019-10-30 2022-08-19 朱诺治疗学有限公司 细胞选择和/或刺激装置及使用方法
US10980836B1 (en) 2019-12-11 2021-04-20 Myeloid Therapeutics, Inc. Therapeutic cell compositions and methods of manufacturing and use thereof
CN115427550A (zh) 2020-01-28 2022-12-02 朱诺治疗学股份有限公司 T细胞转导方法
BR112022020539A2 (pt) 2020-04-10 2023-04-25 Invivyd Inc Compostos específicos para proteína s de coronavírus e usos dos mesmos
EP4150640A1 (en) 2020-05-13 2023-03-22 Juno Therapeutics, Inc. Methods of identifying features associated with clinical response and uses thereof
CN116234558A (zh) 2020-06-26 2023-06-06 朱诺治疗学有限公司 条件性地表达重组受体的工程化t细胞、相关多核苷酸和方法
KR20230090367A (ko) 2020-11-04 2023-06-21 주노 쎄러퓨티크스 인코퍼레이티드 변형된 불변 cd3 이뮤노글로불린 슈퍼패밀리 쇄 유전자좌로부터 키메라 수용체를 발현하는 세포 및 관련 폴리뉴클레오티드 및 방법
WO2022133169A1 (en) 2020-12-18 2022-06-23 Century Therapeutics, Inc. Chimeric antigen receptor systems with adaptable receptor specificity
WO2022148370A1 (en) * 2021-01-05 2022-07-14 Lanova Medicines Development Co., Ltd. Anti-gprc5d monoclonal antibodies and uses thereof
WO2022187406A1 (en) 2021-03-03 2022-09-09 Juno Therapeutics, Inc. Combination of a t cell therapy and a dgk inhibitor
AU2022237618A1 (en) 2021-03-17 2023-10-12 Myeloid Therapeutics, Inc. Engineered chimeric fusion protein compositions and methods of use thereof
AU2022241654A1 (en) 2021-03-22 2023-09-28 Juno Therapeutics, Inc. Methods of determining potency of a therapeutic cell composition
CN117321200A (zh) 2021-03-22 2023-12-29 朱诺治疗学股份有限公司 评估病毒载体颗粒效力的方法
IL307367A (en) * 2021-04-07 2023-11-01 Lg Chemical Ltd GUCY2C binding polypeptide and uses thereof
KR20240018454A (ko) 2021-05-06 2024-02-13 주노 테라퓨틱스 게엠베하 T 세포의 자극 및 형질도입 방법
WO2022247756A1 (zh) * 2021-05-23 2022-12-01 上海邦耀生物科技有限公司 靶向gprc5d的嵌合抗原受体及其用途
CN116063500A (zh) 2021-08-30 2023-05-05 原启生物科技(上海)有限责任公司 抗gprc5d抗原结合蛋白及其用途
MX2024005406A (es) 2021-11-03 2024-08-06 Janssen Biotech Inc Reduccion de corticosteroides en el tratamiento con anticuerpos anti-cd38.
AU2023207739A1 (en) 2022-01-14 2024-08-29 Oricell Therapeutics Co., Ltd. Chimeric antigen receptor targeting gprc5d and use thereof
WO2023147515A1 (en) 2022-01-28 2023-08-03 Juno Therapeutics, Inc. Methods of manufacturing cellular compositions
KR20240137090A (ko) 2022-01-29 2024-09-19 카스젠 라이프 사이언스 씨오., 엘티디. Gprc5d 항체 및 그 용도
US20250297282A1 (en) 2022-05-05 2025-09-25 Juno Therapeutics Gmbh Viral-binding protein and related reagents, articles, and methods of use
WO2023220655A1 (en) 2022-05-11 2023-11-16 Celgene Corporation Methods to overcome drug resistance by re-sensitizing cancer cells to treatment with a prior therapy via treatment with a t cell therapy
IL316839A (en) 2022-05-17 2025-01-01 Umoja Biopharma Inc Production of viral particles
EP4532695A1 (en) 2022-05-25 2025-04-09 Celgene Corporation Methods of manufacturing t cell therapies
IL317532A (en) 2022-06-10 2025-02-01 Umoja Biopharma Inc Engineered stem cells and their uses
US20250177530A1 (en) * 2022-06-24 2025-06-05 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Molecules that bind to enpp1 polypeptides
JP2025525439A (ja) 2022-06-30 2025-08-05 インダプタ セラピューティクス インコーポレイテッド 操作されたナチュラルキラー（ｎｋ）細胞と抗体療法との組み合わせおよび関連する方法
US20240041929A1 (en) 2022-08-05 2024-02-08 Juno Therapeutics, Inc. Chimeric antigen receptors specific for gprc5d and bcma
CN116003598B (zh) 2022-08-30 2024-04-26 苏州缔码生物科技有限公司 靶向人gprc5d的重组人源化单克隆抗体及其应用
KR20250061756A (ko) 2022-09-08 2025-05-08 주노 쎄러퓨티크스 인코퍼레이티드 T 세포 요법과 연속적 또는 간헐적 dgk 억제제 투여의 조합
WO2024097992A2 (en) 2022-11-04 2024-05-10 Umoja Biopharma, Inc. Particles displaying adhesion-molecule fusions
EP4615960A1 (en) 2022-11-09 2025-09-17 C3S2 GmbH Methods for manufacturing engineered immune cells
WO2024102954A1 (en) 2022-11-10 2024-05-16 Massachusetts Institute Of Technology Activation induced clipping system (aics)
WO2024161021A1 (en) 2023-02-03 2024-08-08 Juno Therapeutics Gmbh Methods for non-viral manufacturing of engineered immune cells
WO2024220588A1 (en) 2023-04-18 2024-10-24 Juno Therapeutics, Inc. Cytotoxicity assay for assessing potency of therapeutic cell compositions
WO2024243365A2 (en) 2023-05-23 2024-11-28 Juno Therapeutics, Inc. Activation markers of t cells and method for assessing t cell activation
EP4520346A1 (en) * 2023-09-06 2025-03-12 Gyncentrum Sp. z o.o. Cells, methods and systems for use in the treatment of a cancer with dual-car-t
WO2025059362A1 (en) 2023-09-13 2025-03-20 Juno Therapeutics, Inc. Combination therapies with a cell therapy expressing a gprc5d-targeting car and related methods and uses
WO2025076472A1 (en) 2023-10-06 2025-04-10 Juno Therapeutics, Inc. Combination therapies with a cell therapy expressing a gprc5d-targeting car and related methods and uses
CN117229407B (zh) * 2023-11-14 2024-02-20 成都优赛诺生物科技有限公司 一种靶向gprc5d的单域抗体、嵌合抗原受体及其应用
WO2025129084A1 (en) 2023-12-13 2025-06-19 Umoja Biopharma, Inc. Engineered induced stem cell derived myeloid cells and methods of differentiating and using same
WO2025147545A1 (en) 2024-01-03 2025-07-10 Juno Therapeutics, Inc. Lipid nanoparticles for delivery of nucleic acids and related methods and uses
WO2025231174A1 (en) 2024-04-30 2025-11-06 Umoja Biopharma, Inc. Manufacturing viral particles
WO2025231372A2 (en) 2024-05-03 2025-11-06 Janssen Biotech, Inc. Methods for treating multiple myeloma with car-t cells and bispecific antibodies
WO2025231408A2 (en) 2024-05-03 2025-11-06 Janssen Biotech, Inc. Methods for treating multiple myeloma with car-t cells and bispecific antibodies
WO2025235604A1 (en) 2024-05-08 2025-11-13 Umoja Biopharma, Inc. Fusion protein for use as immune cell engager

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5091513A (en) 1987-05-21 1992-02-25 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US5132405A (en) 1987-05-21 1992-07-21 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
JPS6412935A (en) 1987-07-02 1989-01-17 Mitsubishi Electric Corp Constant-speed travel device for vehicle
US5399346A (en) 1989-06-14 1995-03-21 The United States Of America As Represented By The Department Of Health And Human Services Gene therapy
US6436703B1 (en) 2000-03-31 2002-08-20 Hyseq, Inc. Nucleic acids and polypeptides
MXPA02012434A (es) 2000-06-16 2004-09-06 Cambridge Antibody Tech Anticuerpos que se unen inmunoespecificamente a estimulador de linfocitos ii.
US20030207288A1 (en) 2001-08-20 2003-11-06 Lewin David A. GPCR-like retinoic acid-induced gene 1 protein and nucleic acid
JPWO2003055507A1 (ja) 2001-12-27 2005-04-28 住友製薬株式会社 拒食症又は生活習慣病治療薬及びそのスクリーニング方法
US7446190B2 (en) 2002-05-28 2008-11-04 Sloan-Kettering Institute For Cancer Research Nucleic acids encoding chimeric T cell receptors
US20040110139A1 (en) * 2002-12-10 2004-06-10 Isis Pharmaceuticals Inc. Modulation of G protein-coupled receptor 3 expression
US7276372B2 (en) 2002-12-20 2007-10-02 Pdl Biopharma, Inc. Antibodies against GPR64 and uses thereof
BRPI0407446A (pt) 2003-02-13 2006-01-31 Pharmacia Corp Anticorpos para c-met para o tratamento de cânceres
WO2005019258A2 (en) 2003-08-11 2005-03-03 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
RS53984B1 (sr) * 2003-12-10 2015-10-30 E. R. Squibb & Sons L.L.C. Ip-10 antitela i njihove upotrebe
US20050266008A1 (en) * 2004-03-29 2005-12-01 Medarex, Inc. Human anti-IRTA-5 antibodies
JP5362563B2 (ja) 2006-08-03 2013-12-11 アストラゼネカ・アクチエボラーグ αＶβ６に対する抗体およびその使用
US9512236B2 (en) 2006-12-19 2016-12-06 Ablynx N.V. Amino acid sequences directed against GPCRS and polypeptides comprising the same for the treatment of GPCR-related diseases and disorders
SI2856876T1 (en) 2007-03-30 2018-04-30 Memorial Sloan-Kettering Cancer Center Constitutive expression of costimulatory ligands on adoptively transferred T lymphocytes
CA2699394C (en) 2007-09-17 2020-03-24 The Regents Of The University Of California Internalizing human monoclonal antibodies targeting prostate cancer cells in situ
WO2009051633A1 (en) 2007-10-15 2009-04-23 The Board Of Trustees Of The Leland Stanford Junior University Gpcr crystalization method using an antibody
US7736648B2 (en) * 2007-10-25 2010-06-15 Trellis Bioscience, Inc. Anti-RSV G protein antibodies
CA2715166C (en) 2008-02-11 2017-05-16 Curetech Ltd. Monoclonal antibodies for tumor treatment
US9217032B2 (en) 2010-01-08 2015-12-22 Les Laboratoires Servier Methods for treating colorectal cancer
AU2011282423B2 (en) 2010-07-22 2015-05-14 Schrader, Sabariah Cross-protective pathogen protection, methods and compositions thereof
PH12013501201A1 (en) 2010-12-09 2013-07-29 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
US9833476B2 (en) * 2011-08-31 2017-12-05 The Trustees Of Dartmouth College NKP30 receptor targeted therapeutics
CN103483452B (zh) 2012-06-12 2021-08-13 上海细胞治疗集团有限公司 双信号独立的嵌合抗原受体及其用途
WO2014087010A1 (en) 2012-12-07 2014-06-12 Ablynx N.V. IMPROVED POLYPEPTIDES DIRECTED AGAINST IgE
JO3519B1 (ar) 2013-01-25 2020-07-05 Amgen Inc تركيبات أجسام مضادة لأجل cdh19 و cd3
KR102064230B1 (ko) * 2013-02-15 2020-01-13 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 키메라 항원 수용체 및 이의 이용 방법
US9745368B2 (en) * 2013-03-15 2017-08-29 The Trustees Of The University Of Pennsylvania Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy
WO2014191128A1 (en) * 2013-05-29 2014-12-04 Cellectis Methods for engineering t cells for immunotherapy by using rna-guided cas nuclease system
WO2015142675A2 (en) 2014-03-15 2015-09-24 Novartis Ag Treatment of cancer using chimeric antigen receptor
US9884921B2 (en) 2014-07-01 2018-02-06 Pfizer Inc. Bispecific heterodimeric diabodies and uses thereof
JP2017528433A (ja) 2014-07-21 2017-09-28 ノバルティス アーゲー 低い免疫増強用量のｍＴＯＲ阻害剤とＣＡＲの組み合わせ
SI3227339T1 (sl) 2014-12-05 2022-02-28 Memorial Sloan-Kettering Cancer Center Himerni antigenski receptorji, ki ciljajo na receptor, povezan z G-proteinom, in njihova uporaba
EP3227324A4 (en) 2014-12-05 2018-08-29 Memorial Sloan Kettering Cancer Center Antibodies targeting g-protein coupled receptor and methods of use
RU2022103665A (ru) 2015-10-23 2022-03-05 Еурека Терапьютикс, Инк. Химерные конструкции антитело/t-клеточный рецептор и их применения
NZ743124A (en) 2015-12-04 2022-11-25 Memorial Sloan Kettering Cancer Center Antibodies targeting fc receptor-like 5 and methods of use
CN109715207B (zh) 2016-03-29 2023-03-31 南加利福尼亚大学 靶向癌症的嵌合抗原受体
US11768203B2 (en) 2016-03-31 2023-09-26 University Of Southern California Highly sensitive and specific luciferase based reporter assay for antigen detection
CN112125976B (zh) 2018-01-26 2022-06-03 重庆精准生物技术有限公司 改造的铰链及其在构建car骨架中的应用
JP7742773B2 (ja) 2018-11-01 2025-09-22 ジュノー セラピューティクス インコーポレイテッド Ｇタンパク質共役受容体クラスｃグループ５メンバーｄ（ｇｐｒｃ５ｄ）に特異的なキメラ抗原受容体

Also Published As

Publication number Publication date
IL252621B2 (en) 2024-06-01
US10633426B2 (en) 2020-04-28
AU2022200052A1 (en) 2022-02-03
EP3227339A1 (en) 2017-10-11
JP2023091037A (ja) 2023-06-29
RU2017123551A3 (enExample) 2019-07-17
US20200270328A1 (en) 2020-08-27
IL252621A0 (en) 2017-07-31
HRP20211978T1 (hr) 2022-04-01
AU2015357518A1 (en) 2017-06-29
CA2969864A1 (en) 2016-06-09
BR112017011920A2 (pt) 2018-02-27
CN107428829B (zh) 2021-10-15
RS62870B1 (sr) 2022-02-28
IL310130A (en) 2024-03-01
US10906956B2 (en) 2021-02-02
CN113968912B (zh) 2025-05-16
JP2021040652A (ja) 2021-03-18
EP4015534A1 (en) 2022-06-22
DK3227339T3 (da) 2022-01-10
NZ732574A (en) 2023-11-24
US20180118803A1 (en) 2018-05-03
US20200270326A1 (en) 2020-08-27
IL252621B1 (en) 2024-02-01
PH12017501044A1 (en) 2018-03-05
MX2017007242A (es) 2018-01-25
SMT202200040T1 (it) 2022-03-21
SA517381665B1 (ar) 2022-01-24
HUE057777T2 (hu) 2022-06-28
EP3227339B1 (en) 2021-11-10
CN113968912A (zh) 2022-01-25
CN113683711A (zh) 2021-11-23
RU2017123551A (ru) 2019-01-14
SI3227339T1 (sl) 2022-02-28
US11820806B2 (en) 2023-11-21
KR102612367B1 (ko) 2023-12-12
RU2762359C2 (ru) 2021-12-20
ES2899779T3 (es) 2022-03-14
CY1125008T1 (el) 2022-07-22
US11866478B2 (en) 2024-01-09
MX2021008798A (es) 2021-08-24
MY192065A (en) 2022-07-25
SG11201704547RA (en) 2017-07-28
JP2017537629A (ja) 2017-12-21
KR20170109537A (ko) 2017-09-29
EP3227339A4 (en) 2018-08-08
MX385156B (es) 2025-03-14
CN118271463A (zh) 2024-07-02
LT3227339T (lt) 2022-01-10
SG10202007326QA (en) 2020-08-28
AU2015357518B2 (en) 2021-10-07
US20240294599A1 (en) 2024-09-05
CN107428829A (zh) 2017-12-01
US20200270327A1 (en) 2020-08-27
PL3227339T3 (pl) 2022-02-21
WO2016090312A1 (en) 2016-06-09
JP6919091B2 (ja) 2021-08-18

Similar Documents

Publication Publication Date Title
PT3227339T (pt) Recetores de antigénio quiméricos que têm como alvo o recetor 4 acoplado a proteína g e utilizações dos mesmos
IL283423B (en) Chimeric antigen receptors targeting cd-19
PT3896091T (pt) Recetores de antigénio quiméricos dirigidos a bcma e métodos da sua utilização
IL253909B (en) A chimeric antigen receptor (car) that binds to the extracellular domain of a muc1 and uses thereof
IL258405A (en) Antibody/t-cell receptor chimeric constructs and uses thereof
IL251030B (en) Chimeric antigen receptors
IL252645B (en) Cs1 targeted chimeric antigen receptor-modified t cells
IL256643A (en) Immune checkpoint chimeric antigen receptors therapy
CL2016001879A1 (es) Anticuerpos humanos a pd-l1
PL3436079T3 (pl) Antygen chimeryczny i receptory komórek t oraz sposoby ich stosowania
SI3628687T1 (sl) BCMA himerni antigenski receptorji
HUE047929T2 (hu) Kiméra antigén receptor
PL3283110T3 (pl) Przeciwciała skierowane przeciwko receptorowi interleukiny 36 (il-36r)
DK3149031T3 (da) Anti-human papillomavirus 16 e7 t-cellereceptorer
IL258502A (en) psca-targeted chimeric antigen receptors
DK3191517T3 (da) Krydsreaktive siglec-antistoffer
SI3230310T1 (sl) Anti-CD70 himerni antigenski receptorji
IL263627A (en) Chimeric antigen receptors (cars) specific for muc1 and methods for their use
IL252604A0 (en) Chimeric antigen receptors and methods of use
IL258079B (en) Antigen receptors and uses thereof
EP3294772A4 (en) AGAINST HER2 FACED ANTIGEN BINDING CONSTRUCTS
DK3154587T3 (da) Konjugater omfattende et anti-egfr1-antistof
EP3368076C0 (en) HIGHLY POTENT ANTIBODIES BINDING TO DEATH RECEPTOR 4 AND DEATH RECEPTOR 5
TH1601000713A (th) แอนทิบอดีใหม่ที่ต้าน-ตัวรับ tslp ของมนุษย์
TH1501003909A (th) แอนติบอดีต่อ pdgfr-บีตา และการใช้ของมัน